Program
SYN818
A development code. Also written as “SYN818 and Olaparib will be administered”.
Its studies are mostly in Neoplasm Metastasis, led by Hangzhou SynRx Therapeutics Biomedical Technology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hangzhou SynRx Therapeutics Biomedical Technology | 22 open or running | phase 1since Oct 29, 2024 | Oct 29, 2024 | Aug 25, 2028phase 1 · NCT07156253 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 29, 2024First study: phase 1 study in Neoplasm MetastasisFirst studyNCT06666270 · 30 planned · China
- Aug 27, 2025Phase 1 study in Neoplasm MetastasisNCT07156253 · 110 planned · China
Ahead
- Aug 25, 2028Primary completion: phase 1 study in Neoplasm MetastasisNCT07156253
TargetBeta
“A First-in-human, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of SYN818, a DNA Polymerase Theta (POLQ) Inhibitor Alone in Patients With Locally Advanced or Metastatic Solid Tumors”study text, by rule · the study
Other programs on POLQ
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Polymerase Theta Helicase Inhibitor AZD4956 | AstraZeneca | phase 2 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07156253Neoplasm Metastasis · China | 1 | Recruiting | Aug 25, 2028 | 110 |
| NCT06666270Neoplasm Metastasis · China | 1 | Recruiting | Jun 30, 2026 | 30 |
How it is read
Names in the registry
- “SYN818 and Olaparib will be administered”, 1 entry
- “SYN818”, 1 entry
Codes read as this program: SYN818.
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.